A paradigm shift. Defensive strategies for the treatment of localized prostate cancer in the new S3 guideline;Ein paradigmenwechsel defensive strategien zur behandlung des lokal begrenzten prostatakarzinoms in der neuen S3-leitlinie

Urologe - Ausgabe A

Volumn 49, Issue 2, 2010, Pages 199-205

  Weissbach L ^a   Schaefer, C ^b   Heidenreich, A ^c  

^a Stiftung Männergesundheit ^*  (Germany)

^b Arztliches Zentrum fur Qualitat in der Medizin   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

"Active surveillance"; "Watchful waiting"; Defensive strategies; Localized prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER THERAPY; EARLY DIAGNOSIS; HUMAN; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; S3 GUIDELINE; TREATMENT INDICATION; TREATMENT PLANNING; WATCHFUL WAITING;

CROSS-SECTIONAL STUDIES; DEFENSIVE MEDICINE; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952621817     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-010-2236-5     Document Type: Review

References (26)

1. Beck-Bornholdt HP (2003) Der Schein der Weisen. Rowohldt, Leipzig
2. Berglund RK, Masterson TA, Vora KC (2008) Pathological upgrading an up staging with immediate repeat biopsy in patients eligible for AS. J Urol 180(5):1964-1967
3. Beske F, Katalinic A, Peters E, Pritzkuleit R (2009) Morbiditä tsprognose 2050, Bd. 114. Ausgewählte Krankheiten für Deutschland, Brandenburg und Schleswig-Holstein. Schriftenreihe/Fritz Beske Institut für Gesundheits-System-Forschung, Kiel
4. Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. Scandinavian prostate cancer group study no. 4. N Engl J Med 352(19):1977-1984
5. Bill-Axelson A, Holmberg L, Filén F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. Scandinavian prostate cancer group study number 4. J Natl Cancer Inst 100(16):1144-1154
6. Capitanio U, Scattoni V, Freschi M et al (2008) Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 54(1):118-125
7. Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Urologic Strategic Research Endeavour (CaPSURE), a National Disease Registry. J Urol 171:1393-1401
8. Dall'Era MA, Konety BR, Cowan JE et al (2008) Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112(12):2664-2670 (Pubitemid 351969209)
9. DRG-Statistik(2006) InEK: Datenveröffentlichung gem. §21 KHEntgG http://www.g-drg.de/cms/index.php/inek-site-de/content/view/full/1629
10. Kakehi Y, Kamoto T, Shiaishi T et al (2008) Prospective evaluation of selection criteria for AS in Japanese patients with stage T1 NOMO prostate cancer. Jpn J Clin Oncol 38(2):122-128 (Pubitemid 351337956)
11. Klotz L, Nam R, Lam A et al (2009) Clinical results of long term follow-up of a large active surveillance cohort. J Urol 184(4):606
12. NICE (2009) NICE Guideline No. 58. http://www.nice.org.uk/guidance/index. jsp?action=byID&o=11924
13. Otabi M, Ross P et al (2008) Role of repeated biopsy of the prostate In predicting disease progression In patients with prostate cancer on active surveillance. Cancer 113:286-292
14. Parker C (2004) Active surveillance: towards a new paradigm In the management of early prostate cancer. Lancet Oncol 5:101-106
15. Parker C, Muston D, Melia J et al (2006) A model of the natural history of screen-detected prostate cancer and the effect of radical treatment on overall survival. Br J Cancer 94(10):1361-1368 (Pubitemid 43772267)
16. Schröder FH, Hugosson J, Robool MJ (2009) Screening and prostate-cancer mortality In a randomized European study. N Engl J Med 360(13):1320-1328
17. Schröder FH (2008) Screening for prostate cancer (PC)-an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 26(5):533-541
18. SEER (2009) SEER-Datenbank, http://www.seer. cancer.gov/statfacts/html/ prost.html?statfactspage=prost.html& x=18&y=16
19. Sengupta S, Blute ML, Bagniewski SM et al (2008) After radical retropubic prostatectomy "insignificant" prostate cancer has a risk of progression similar to low risk "significant" cancer. BJU Int 101:170-174
20. Soloway MS, Soloway CT, Williams S et al (2008) Active surveillance; a reasonable management alternative for patients with prostate cancer: the miami experience. BJU Int 101(2):165-169 (Pubitemid 350294039)
21. Steyerberg EW, Roobol MJ, Kattan MW (2007) Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177(1):107-112 (Pubitemid 44879468)
22. Studer UE, Whelan P, Albrecht W et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC)Trial 30891. J Clin Oncol 24(12):1868-1876 (Pubitemid 46638985)
23. Tumorzentrum Brandenburg (2008) Tumorzentrum Brandenburg Qualitätsbericht, http:// www.tumorzentrum-brandenburg.de/PWP/ (S(y2haxr55u552dukrq0tl5jx))/uploads/Sachbericht-2008%5B1%5D.pdf
24. Bergh RC van den, Roemeling S, Roobol MJ et al (2008) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55(1):1-8
25. Walsh PC, DeWeese TL, Eisenberger MA (2007) Clinical practice. Localized prostate cancer. N Engl J Med 357:2696-2705
26. Zietman A (2008) AS - a safe, low-cost prognostic test for prostate cancer. BJU Int 101(9):1059-1060